Table 1.

Characteristics of included studies.

Study	Country	Sample size (n = )	Patients with RVD or pulmonary vascular dysfunction (n=)	Type	Non-survivors in patients with RVD or pulmonary vascular dysfunction (n=)	Non-survivors in patients without RVD or pulmonary vascular dysfunction (n=)	Definition of RVD	Diagnosticmodality:TTE/TEE/PAC	outcome
Florence Boissier et al.2	France	226	49	P	28	63	ACP	TEE	28-day mortality
David Osman et al.3	France	145	14	P	9	73	ACP	PAC	28-day mortality
Antoine Vieillard-Baron et al.4	France	75	19	P	6	18	ACP	TEE	28-day mortality
C. Lazzeri et al.7	Italy	121	44	P	28	24	other	TEE/TTE	ICU mortality
Zhang et al.8	China	21	6	R	5	4	ACP	TEE	ICU mortality
Armand Mekontso Dessap et al.9	France	752	164	P	78	244	ACP	TEE	Hospital mortality
Annick Legras et al.10	France	195	36	P	10	35	ACP	TTE/TEE	28-day mortality
Jer´ ome Fichet et al.11	Canada	50	15	R	3	12	other	TTE	ICU Mortality
Gwenae¨lle Lhe´ritier et al.12	France	200	45	P	11	35	ACP	TEE	28-day mortality
Todd M. Bull et al.13	USA	475	349	P	103	24	other	PAC	60-day mortality
Manuela Bonizzoli et al.14	Italy	28	25	P	9	1	other	TEE	ICU mortality
Wu et al.15	China	31	14	P	7	2	ACP	TTE	28-day mortality

RVD: right ventricular dysfunction; ACP: acute cor pulmonale; TEE: transesophageal echocardiography; TTE: transthoracic echocardiography; PAC: pulmonary artery catheter; P:Prospective observational; R:Retrospective.